Glucosamine is an amino sugar that the body makes naturally and uses as a building block for cartilage and other connective tissue; chondroitin (chondroitin sulfate) is a related molecule that is likewise a natural structural component of joint cartilage. As a supplement, glucosamine is sold mainly as glucosamine sulfate or glucosamine hydrochloride — two different salts that are NOT interchangeable — and is most often manufactured from the shells of shellfish such as shrimp, crab, and lobster (grain- or corn-fermentation "shellfish-free" versions also exist). It is frequently paired with chondroitin sulfate, usually extracted from cow (bovine) or shark cartilage. Both are regulated as dietary supplements and are NOT reviewed or approved by the FDA before sale.
Glucosamine and chondroitin are among the best-selling supplements in the U.S., marketed as joint "rebuilders" that regrow cartilage, "lubricate" stiff knees, and reverse arthritis. The government science is far more sober. NCCIH states plainly that "It's still uncertain whether glucosamine and chondroitin are helpful for knee osteoarthritis symptoms" and that "Whether glucosamine and chondroitin actually have an effect on joint structure is uncertain," noting that the results of individual studies "were inconsistent." The single largest, independent, NIH-funded trial — GAIT (Clegg et al., New England Journal of Medicine 2006, 1,583 patients) — found no significant pain benefit over placebo for the overall group, and the 2019 American College of Rheumatology/Arthritis Foundation guideline (cited by NCCIH) strongly recommends AGAINST glucosamine, alone or with chondroitin, for knee osteoarthritis because "the best data do not show any important benefits." As dietary supplements they are not FDA-approved and cannot legally be sold to treat, cure, or prevent any disease; the popular "cartilage regrowth" framing is not supported by the human evidence.
The largest independent trial, the NIH-funded GAIT trial (Clegg et al., NEJM 2006, 1,583 patients), found that at its primary 24-week endpoint (a 20% drop in knee pain) neither glucosamine (64.0% responders, P=0.30), chondroitin (65.4%, P=0.17), nor the combination (66.6%, P=0.09) beat placebo (60.1%); the authors concluded the supplements 'did not reduce pain effectively in the overall group of patients with osteoarthritis of the knee.' NCCIH says 'It's still uncertain whether glucosamine and chondroitin are helpful for knee osteoarthritis symptoms,' and the 2019 American College of Rheumatology/Arthritis Foundation guideline strongly recommends AGAINST glucosamine for knee OA because 'the best data do not show any important benefits.' The biggest, best-designed independent evidence shows no benefit.
In a secondary subgroup analysis of GAIT (Clegg 2006), participants with moderate-to-severe pain responded to the glucosamine+chondroitin combination more often than to placebo (79.2% vs. 54.3%, P=0.002). But this was NOT the trial's prespecified primary endpoint, it came from a smaller subgroup, and it is best treated as a hypothesis-generating signal that later, larger analyses did not definitively confirm. A possible signal worth noting honestly — not proof, and not a basis for a firm claim.
The Cochrane review (Towheed et al. 2005, 20 RCTs, 2,570 patients) found benefit concentrated in trials of one manufacturer's glucosamine-sulfate preparation: pooled results 'from studies using a non-Rotta preparation or adequate allocation concealment failed to show benefit in pain and WOMAC function while those studies evaluating the Rotta preparation showed that glucosamine was superior to placebo.' When analysis was restricted to the eight studies with adequate allocation concealment, glucosamine showed NO benefit for pain or WOMAC function. Because the positive data cluster in industry-linked trials of one branded sulfate product and are not confirmed by higher-quality independent research, the evidence conflicts — the marketing claim that 'the sulfate form is the real one' is not established.
The 2-year GAIT structure study (Sawitzke et al., Arthritis & Rheumatism 2008, 572 patients) measured knee joint-space width over 24 months and concluded that 'at 2 years, no treatment achieved a predefined threshold of clinically important difference in JSW loss as compared with placebo.' NCCIH states that 'Whether glucosamine and chondroitin actually have an effect on joint structure is uncertain,' and the NIH's MedlinePlus tells patients these supplements 'do not seem to help the joint grow new cartilage or keep arthritis from getting worse.' The evidence on joint structure is inconsistent, and no reliable, consistent human data show that these supplements protect cartilage or modify the underlying disease.
Per NCCIH, 'moderate-strength evidence does not support the use of glucosamine sulfate for hip osteoarthritis.' For the hand, a single trial found that chondroitin improved pain and function more than placebo; and for the temporomandibular (jaw) joint, a review reported that using glucosamine for 3 months or more was associated with reduced pain and improved mouth opening, though the reviewers were unable to reach definite conclusions. These are isolated, single-study or unconfirmed signals rather than robust evidence, and there is no good human evidence for a general anti-inflammatory or whole-body joint benefit beyond the (already weak and largely negative) knee data.
No FDA-approved or official dose exists, and glucosamine sulfate and glucosamine hydrochloride are not interchangeable. The amounts used in the major osteoarthritis trials were glucosamine 1,500 mg per day (in the NIH GAIT trial, 500 mg of glucosamine hydrochloride three times daily; many European trials instead used glucosamine sulfate 1,500 mg once daily) and, when combined, chondroitin sulfate 1,200 mg per day (400 mg three times daily). Trials ran for months — GAIT assessed pain at 24 weeks and joint structure over 2 years — so any effect, if it occurs at all, would be gradual rather than immediate. Products vary widely in salt form, dose, and whether they include chondroitin, so one "1,500 mg" product is not equivalent to another. This is general information drawn from the published trials, not personalized medical advice.
Glucosamine and chondroitin are generally well tolerated. NCCIH reports that "No major safety problems have been identified in large studies of glucosamine and chondroitin for osteoarthritis." The most common side effects are mild and gastrointestinal — such as nausea, heartburn, diarrhea, or constipation. IMPORTANT INTERACTIONS AND CAUTIONS: (1) Warfarin / blood thinners — NCCIH warns that glucosamine and chondroitin "have been associated with an increased risk of bleeding in people who are taking the anticoagulant warfarin"; use caution with any anticoagulant or antiplatelet drug and before surgery, and tell your prescriber. (2) Blood sugar — NCCIH notes "glucosamine may cause increases in blood glucose (sugar) levels in some people," so people with diabetes or prediabetes should monitor their levels and check with their clinician. (3) Pregnancy and breastfeeding — "Little is known about the safety of using glucosamine and chondroitin during pregnancy or while breastfeeding," so avoid unless a clinician advises otherwise. (4) Shellfish allergy — most glucosamine is manufactured from the shells of shrimp, crab, and lobster and is commonly labeled as shellfish-derived; if you have a shellfish allergy, read the label and ask your pharmacist or clinician first, or choose a fermentation-derived "shellfish-free" product. Because these are dietary supplements, their contents are not FDA-verified against the label, so look for third-party testing (USP, NSF). They are not FDA-approved to treat any disease.
Glucosamine and chondroitin are safe for most people and inexpensive to try, but the honest weight of the evidence is disappointing: the largest independent trial (NIH's GAIT) found them no better than placebo for overall knee osteoarthritis pain, the 2-year data showed they did not slow joint-space loss, and the 2019 American College of Rheumatology guideline strongly recommends against them for knee OA. The genuinely positive results cluster in industry-funded trials of one patented glucosamine-sulfate product and in an exploratory moderate-to-severe-pain subgroup — real signals, but not proof, and not confirmed by higher-quality independent studies. These supplements are not FDA-approved to treat arthritis and do not "rebuild" cartilage. If your OA pain is significant, the higher-value step is a conversation with a clinician about proven options. If you still want to trial glucosamine/chondroitin for a couple of months to see whether your knees feel better, that is reasonable for many people — but check first if you take warfarin or other blood thinners, have diabetes, are pregnant or breastfeeding, or have a shellfish allergy, and stop if you notice no benefit. This is general information, not medical advice; talk to your doctor or pharmacist before starting any supplement.
General information, not medical advice. Dietary supplements are not FDA-approved to treat, cure, or prevent any disease, and quality/purity vary by brand. Talk to your clinician or pharmacist before starting one — especially if you’re pregnant, breastfeeding, or take other medicines.